

Table S1. Characteristics of participants

Baseline clinical characteristics	CD Spanish cohort (n=34)	CD Healthy Relatives Spanish cohort (n=29)
Male/female (%)	13/21 (38.2/61.7)	12/17 (41.3/58.7)
Median (IQR) age at surgery (years) or at sample collection	34 (18 – 58)	36 (18 – 58)
Median duration of disease (IQR) at surgery (years) or at sampling	6.5 (0 – 28)	
Maximum disease location (Montreal classification)		
<i>L1 ileal (%)</i>	12 (35)	
<i>L2 colonic (%)</i>	0 (0)	
<i>L3 ileocolonic (%)</i>	22 (64.7)	
<i>L4 isolated upper disease (%)</i>	2 (5.8)	
Disease behaviour at surgery (Montreal classification)		
<i>B1 non-stricturing, non-penetrating (%)</i>	3 (8.8)	
<i>B2 stricturing (%)</i>	22 (64.7)	
<i>B3 penetrating (%)</i>	5 (14.7)	
<i>p perianal disease (%)</i>	3 (8.8)	
Active smoking at surgery (%)	10 (29.4)	
Medication at surgery or at sampling		
<i>Mesalamine-sulfasalazine (%)</i>	4 (11.8)	
<i>Corticosteroids (%)</i>	2 (2.9)	
<i>Immunosuppressants (%)</i>	14 (41.1)	
<i>Anti-TNF (%)</i>	12 (23.5)	
<i>Antibiotics (%)</i>	0 (0)	
<i>Methotrexate</i>	1 (2.9)	
<i>Other</i>	10 (29.4)	
<i>None</i>	1 (2.9)	
Baseline clinical characteristics	CD Belgian cohort (n=55)	
Male/female (%)	28/25 (52.8/47.2)	
Median (IQR) age at surgery (years) or at sample collection	41.3 (26.5 – 52.9)	
Median duration of disease (IQR) at surgery (years) or at sampling	15.7 (4.1 – 27.1)	
Maximum disease location (Montreal classification)		
<i>L1 ileal (%)</i>	18 (34)	
<i>L2 colonic (%)</i>	0 (0)	
<i>L3 ileocolonic (%)</i>	35 (66)	
<i>L4 isolated upper disease (%)</i>	2 (3.8)	
Disease behaviour at surgery (Montreal classification)		
<i>B1 non-stricturing, non-penetrating (%)</i>	2 (3.8)	
<i>B2 stricturing (%)</i>	21 (39.6)	
<i>B3 penetrating (%)</i>	30 (56.6)	
<i>p perianal disease (%)</i>	15 (28.3)	
Active smoking at surgery (%)	16 (30.2)	
Medication at surgery or at sampling		
<i>Mesalamine-sulfasalazine (%)</i>	4 (7.5)	
<i>Corticosteroids (%)</i>	10 (18.9)	
<i>Immunosuppressants (%)</i>	12 (22.6)	
<i>Anti-TNF (%)</i>	7 (13.2)	
<i>Antibiotics (%)</i>	9 (16.9)	
<i>Methotrexate</i>		
<i>Other</i>		
<i>None</i>		
Baseline clinical characteristics	UC Spanish cohort (n=31)	UC Healthy Relatives Spanish cohort (n=29)
Male/female (%)	9/24 (27.2/72.7)	9/20 (31.03/68.96)
Median (IQR) age at sample collection	43 (24 – 62)	38 (22 – 60)
Median duration of disease (IQR) at sampling	9 (1 – 23)	
Disease behaviour at sampling		
<i>E1 proctitis</i>	9 (27.3)	
<i>E2 left sided colitis</i>	11 (33.3)	
<i>E3 pancolitis</i>	11 (33.3)	
Medication at sampling		
<i>Mesalamine (%)</i>	11 (24)	
<i>Corticosteroids (%)</i>	2 (6)	
<i>Immunosuppressants (%)</i>	8 (24)	
<i>Other</i>	2 (6)	
<i>None</i>		
Characteristics	Related Healthy Controls (n=28)	
Age (years)	27 (20 - 64)	
Weight (Kg)	59,75 (48,5 - 92)	
Height (cm)	168 (154 - 192)	
BMI(kg/m2)	21.4 (19.2 - 28.6)	
Sex		
Female	19 (68%)	
Male	9 (32%)	
Smoker		
Non-smoker	21 (75%)	
Smoker	1 (3.57%)	
Unknown	6 (21.42%)	